 | |
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA |
| Drug class | Monoamine releasing agent;Monoamine reuptake inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H17NO3 |
| Molar mass | 235.283 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Propylone, also known as3,4-methylenedioxy-N-propylcathinone is a mixedmonoamine releasing agent andreupake inhibitor of thecathinone family related tomethylone andethylone.[1]
It acts specifically as a weakpartialserotonin–dopamine releasing agent (SDRA) andserotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), withEC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values for induction of monoamine release of 3,128 nM (30%) forserotonin and 976 nM (20%) fordopamine, andIC50Tooltip half-maximal inhibitory concentration value for monoamine reuptake inhibition of 2,462 nM for serotonin, 28,540 nM for norepinephrine, and 1,863 nM for dopamine.[1]
The drug was first described in the literature in a 1996patent byAlexander Shulgin andPeyton Jacob III.[2] It was subsequently characterized more thoroughly by 2015[1] and was encountered as a noveldesigner drug inEurope by 2016.[3][4][5]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byadding missing information. |
